

演講大綱/Abstracts

日期:2020 年 3 月 21 日

地點: 台北萬豪

2020 胃胰癌 Neo-adjuvant 論壇

Time	Topic	Speaker	Moderator
13:30-14:00	Registration		
14:00-14:10 (10")	Opening	陳立宗 理事長 中華民國癌症醫學會 陳以書 理事長 內視鏡外科醫學會	
14:10-14:40 (30")	Finding HITS in non-CRC GI cancers (Immunotherapy and Targeted Therapy)	邀約中	陳立宗 所長 國衛院
14:40-15:05 (25")	Overview of neo-adjuvant/peri-operative chemotherapy in gastric cancer	陳明晃 醫師 台北榮總	趙毅 部主任 台北榮總
15:05-15:20 (15")	VGH experience	陳明晃 醫師 台北榮總	趙毅 部主任 台北榮總
15:20-15:35 (15")	KMU experience	李京鎔 醫師 高醫	王照元 副院長 高醫
15:35-15:50 (15")	NCKU experience	邀約中	沈延盛 院長 成大醫學院
15:50-16:20 (30")	Discussion	陳仁熙 主任 林口長庚 陳以書 主任 高雄榮總	
16:20-16:40 (20")	Break		
16:40-17:05 (25")	Overview of neo-adjuvant and conversion therapy in pancreatic cancer	沈延盛 院長 成大醫學院	葉大森 部長 林口長庚外科部
17:05-17:20" (15")	NCKU experience	沈延盛 院長 成大醫學院	葉俊男 主任 林口長庚
17:20-17:35" (15")	NTU experience	吳健暉 醫師 台大醫院	田郁文 教授 台大醫院
17:35-18:05 (30")	Discussion	陳仁熙 主任 林口長庚 田郁文 教授 台大醫院	

18:05-18:10 (5")	Closing remarks	陳立宗 所長 國衛院
---------------------	-----------------	---------------

Topic: Finding HITS in non-CRC GI cancers (Immunotherapy and Target Therapy)

Speaker: 邀約中

In contrast to other tumor types, immunotherapy and target therapy treatment has not yet become a relevant part of the treatment landscape of non-CRC gastrointestinal cancer. Immunotherapy is still used in second line or beyond metastatic gastric cancer. Trastuzumab is the only target therapy for advanced gastric cancer in Her 2 over-expression gastric cancer. Recent breakthrough in pancreatic cancer is olaparib maintenance for germline BRCA-mutated metastatic pancreatic cancer, this is the first target therapy with meaning progression free survival benefit of 3.6 months. What are the biomarkers available for first line or early line of treatment? In this presentation, current status and future developments of biomarkers will be discussed.

Gastric Cancer

Topic: Overview of neo-adjuvant chemotherapy in gastric cancer

Speaker: 北榮 陳明晃醫師

In Taiwan, gastric cancer is ranked ninth in newly incidences and seventh in death in 2016. Each year nearly 3600 patients are diagnosed with gastric cancer and around 2400 patients death from it. Although there has been some advancement with target therapies and immunotherapies in the metastatic setting, the role of these agents in resectable setting is still unclear. Chemotherapy remains to be the standard adjuvant therapy after surgery for stage II-III gastric cancer. In addition to adjuvant chemotherapy, neo-adjuvant and peri-operative chemotherapy also have an important role. Recent studies in West (FLOT) and East (PRODIGY, RESOLVE) showed peri-operative and neo-adjuvant can improve RO rate and survival. In this presentation, I will summarize the current status and future developments of perioperative chemotherapy in gastric cancer attempting to find clear answers to the real problems in clinical practice.

Topic: VGH experience sharing

Speaker: 北榮 陳明晃醫師

本演講將分享台北榮總 FLOT NEO-ADJUVANT 案例報告

Topic: KMU experience sharing

Speaker: 高醫 李京鎔 醫師

案例報告 In my presentation, an observation study of comparison of efficacy and safety between preoperative neo-adjuvant concurrent chemoradiotherapy and chemotherapy for patients with locally advanced or metastatic gastric cancer will be present. This is a retrospective data analysis of patient treated between 2010 to 2019. Our study showed neo-adjuvant CCRT may have a favorable OS and PFS.

Topic: NCKU experience

Speaker: 邀約中 (確認中)

本演講將分享成大醫院 NEO-ADJUVANT 案例報告，以及未來 TCTC 將要執行 NEO-ADJUVANT 試驗說明。

Pancreatic Cancer

Topic: Overview of neo-adjuvant and conversion therapy in pancreatic cancer

Speaker: 成大醫學院 沈延盛 院長

Pancreatic cancer is one of the leading causes of cancer death, it is estimated by 2020, pancreatic cancer will become the second leading cause of death in the States. The incidence of pancreatic cancer is increasing each year in Taiwan. Most of the patients are found unresectable. Recent studies have shown for patients who can undergone surgery, the survival rate will increase. In this talk, I will review current advancement of neo-adjuvant and conversion therapy in pancreatic cancer.

Topic: NCKU experience

Speaker: 成大醫學院 沈延盛 院長

本演講將分享成大醫院針對 metastatic pancreatic cancer 給予化學治療後成功給予手術案例報告

Topic NTU experience

Speaker: 臺大醫院 吳健暉 醫師

本演講將分享台大醫院 FOLFIRINOX 案例報告